Next |
home / stock / nltx / nltx message board
Subject | By | Source | When |
---|---|---|---|
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 04/30/2023 9:18:28 PM |
52WK RANGE 0.38 - 1.56 | mick | investorshub | 04/15/2023 3:33:30 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 04/15/2023 3:32:51 PM |
znewcar1: $NLTX 35% v10,8M c.72 f42,594M H.7595 ML.49 gapNgo | znewcar1 | investorshangout | 03/09/2023 11:16:35 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 02/27/2023 12:31:05 AM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 02/21/2023 10:32:21 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 02/05/2023 11:03:03 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 12/18/2022 10:17:54 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 10/23/2022 5:07:48 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 08/31/2022 9:53:53 PM |
$NLTX Neoleukin Therapeutics Inc | mick | investorshub | 07/17/2022 9:35:31 PM |
Neoleukin Therapeuti ($NLTX) | mick | investorshub | 06/04/2022 9:23:35 PM |
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at | mick | investorshub | 05/01/2022 7:36:41 PM |
Neoleukin Therapeuti ($NLTX) | mick | investorshub | 05/01/2022 7:36:22 PM |
Neoleukin Therapeutics Is Maintained at Overweight by Piper Sandler | crudeoil24 | investorshub | 04/04/2022 5:48:03 PM |
NLTX moving up before $ACCR > Neoleukin Therapeutics, | crudeoil24 | investorshub | 04/04/2022 5:32:35 PM |
Neoleukin Therapeuti ($NLTX) | mick | investorshub | 03/12/2022 7:41:36 PM |
Neoleukin Therapeuti ($NLTX) | mick | investorshub | 02/06/2022 9:48:29 PM |
Neoleukin Therapeuti ($NLTX) | mick | investorshub | 01/05/2022 2:30:54 AM |
thank you good repore' $nltx | mick | investorshub | 01/05/2022 2:30:14 AM |
News, Short Squeeze, Breakout and More Instantly...
Neoleukin Therapeutics Inc. Company Name:
NLTX Stock Symbol:
NYSE Market:
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its B...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Neoleukin Therapeutics Inc. (NLTX) is expected to report $-0.8 for Q3 2023